Bone Biologics Corp. (NASDAQ:BBLG) Sees Large Decline in Short Interest

Bone Biologics Corp. (NASDAQ:BBLG) was the recipient of a large drop in short interest during the month of April. As of April 15th, there was short interest totaling 7,180 shares, a drop of 49.9% from the March 31st total of 14,344 shares. Approximately 0.4% of the shares of the company are short sold. Based on an average daily volume of 12,066 shares, the days-to-cover ratio is currently 0.6 days.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bone Biologics in a research report on Friday, March 27th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Bone Biologics presently has an average rating of “Sell”.

Bone Biologics Stock Down 0.7%

Shares of Bone Biologics stock opened at $1.35 on Monday. The firm has a market capitalization of $2.43 million, a P/E ratio of -0.36 and a beta of 0.72. The company has a 50 day moving average price of $1.23 and a 200 day moving average price of $1.60. Bone Biologics has a 52 week low of $1.05 and a 52 week high of $6.75.

Bone Biologics (NASDAQ:BBLG) last announced its quarterly earnings data on Monday, March 2nd. The company reported ($0.34) EPS for the quarter, meeting the consensus estimate of ($0.34). As a group, research analysts anticipate that Bone Biologics will post -1.93 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bone Biologics

An institutional investor recently raised its position in Bone Biologics stock. DRW Securities LLC boosted its holdings in shares of Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 23,576 shares of the company’s stock after buying an additional 12,549 shares during the quarter. DRW Securities LLC owned 1.31% of Bone Biologics worth $34,000 at the end of the most recent reporting period. 34.30% of the stock is owned by hedge funds and other institutional investors.

Bone Biologics Company Profile

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.